

## Shares Magazine

### Chi-Med unit achieves primary endpoint in POC trial

30 March 2015

Hutchison MediPharma - Hutchison China MediTech's majority owned drug R&D company - successfully achieved the primary endpoint in the first proof-of-concept trial of fruquintinib in patients with metastatic colorectal cancer in China. The top-line results demonstrated that the trial clearly succeeded in meeting the primary efficacy endpoint of progression free survival. Assessment of secondary efficacy endpoints, including objective response rate, disease control rate, and overall survival is ongoing, with all appearing in-line with expectations at the February 2015 six-month data cut-off. The adverse events demonstrated in this POC study are consistent with the known safety profile for fruquintinib without major unexpected safety issues. Full detailed results from this trial will be disclosed in due course.

At 8:41am: (LON:HCM) Hutchison China Meditech Ltd share price was +5p at 1295p

Hutchison China Meditech (HCM)

1,295.00p

+5.00p(+0.39%)

delayed 08:56AM

Price delayed by 15  
minutes.